Oncology

Latest News

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com

Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

By AJMC Contributor

May 12th 2025

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 2nd 2015

Genentech's Anti-PD-L1 Agent Receives Breakthrough Status in Advanced NSCLC

With 3 I-O agents have already been approved for metastatic melanoma, 2 from BMS and 1 from Merck, the race for NSCLC has tightened with multiple ongoing clinical trials.

January 30th 2015

Dendreon Sees Light at the End of the Provenge Tunnel

The Canadian company Valeant Pharmaceuticals International Inc has reached an agreement to buy the prostate cancer immunotherapy from Dendreon Corp.

January 30th 2015

Precision Oncology Clinical Service Partnership Announced

The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.

Dr Howard K. Kaufman on the Need for More Diverse Populations in Clinical Trials

January 30th 2015

Dr Howard K. Kaufman on the Need for More Diverse Populations in Clinical Trials

Clinical trials are critical for pushing the oncology field forward, but there is a need for not only more patients to participate in clinical trials, but for a more diverse population, said Howard K. Kaufman, MD, FACS.

The Role of mHealth in Oncology

January 29th 2015

The Role of mHealth in Oncology

Mobile health (mHealth) can be so much more than smartphone apps, and it is a growing movement in the United States that can empower patients, providers, and payers, according to Meg Maley, RN, BSN, founder and CEO of CanSurround.

January 29th 2015

Imbruvica Approved for Waldenstrom's Macroglobulinemia

The drug, jointly developed by Pharmacyclics and Janssen Biotech, has received prior approvals for 3 other indications.

January 29th 2015

Smoking Promotes Disease Progression in Prostate Cancer, Study Reports

Smokers diagnosed with prostate cancer who were treated with radiation were at a greater risk of their cancer returning, metastasizing, and ultimately causing death. Former smokers, however, did not have the increased risk.

January 29th 2015

Eli Lilly Expects Multiple Stakeholders Will Benefit from CII, a PACE Initiative

PACE has launched an evidence-based online tool, Continuous Online Indicators, which will provide information on research progress in 12 tumor types.

Segment 11: Two Paradigms Being Presented in Medical Oncology

January 28th 2015

Segment 11: Two Paradigms Being Presented in Medical Oncology

Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology: one where people would rather be overtreated rather than miss a chance to benefit by being undertreated and another where a person might not be willing to do something until they learn there is a reason to do so.

Segment 10: The Important Distinction Between Diagnostic, Screening Tests

January 28th 2015

Segment 10: The Important Distinction Between Diagnostic, Screening Tests

There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making-although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.

Segment 9: Who Should Order the Test?

January 28th 2015

Segment 9: Who Should Order the Test?

Both Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, agree that the role of genetic counselors should be limited when order diagnostic tests in medical oncology.

Segment 7: Guidelines for Diagnostic Test Use

January 28th 2015

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

Segment 6: Learning About CancerLinQ as It Rolls Out

January 28th 2015

Segment 6: Learning About CancerLinQ as It Rolls Out

Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.

Segment 5: Proper Use of Tests

January 28th 2015

Segment 5: Proper Use of Tests

Bryan Loy, MD, MBA, discusses how payers can measure diagnostic test use and results, and Daniel Hayes, MD, weighs in with how CancerLinQ from the American Society of Clinical Oncology can help.

Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market

January 28th 2015

Segment 4: The FDA Takes Initiative to Regulate the Diagnostic Test Market

Daniel F. Hayes, MD, discusses the FDA's announcement that it will begin to regulate laboratory-developed tests and his belief that it will not squash innovation in the field.

January 28th 2015

Amgen-Onyx File for Full Approval for Kyprolis in MM

Kyprlois is currently approval for use in multiple myeloma patients who have progressed on 2 prior therapies.

Dr Yousuf Zafar Explains How Financial Toxicity Impacts Cancer Patients

January 28th 2015

Dr Yousuf Zafar Explains How Financial Toxicity Impacts Cancer Patients

The term financial toxicity is relatively new and is being used to draw parallels between the physical toxicities of chemotherapy and the cost-related burdens cancer patients face.

January 28th 2015

Screening Does Not Save Lives Except in Very Few Exceptions

Laura Joszt, MA

Screening for deadly illnesses does not necessarily save lives despite assumptions otherwise, according to a study published in the International Journal of Epidemiology.

Two Years In: The Impact of the ACA on Oncology

January 28th 2015

Two Years In: The Impact of the ACA on Oncology

Although the Affordable Care Act (ACA) was signed into law more than 4 years ago, many aspects of it are fairly new, which makes it difficult to analyze the impact the law has had on the United States healthcare system.

January 28th 2015

Pharma Expects Push-Back on Cancer Drug Costs

After Steven Miller, CMO at Express Scripts, announced last week that his company would like to influence the oncology market, Pharma seems to have paid heed.

January 28th 2015

Study Shows Targeted Biopsy Better Than Standard Biopsy, in Prostate Cancer

Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a large-scale study.

Segment 2: Buyer Beware in the Diagnostic Test Market

January 27th 2015

Segment 2: Buyer Beware in the Diagnostic Test Market

There are currently 2 ways diagnostic tests can make it to market in the US: either through the FDA or laboratory-developed tests. This dual-pathway situation has led to a "buyer beware" market, according to Daniel F. Hayes, MD.

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

January 27th 2015

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

Although there have been some accusations of "cookbook medicine" with regards to measurement guidelines, panelists Dennis Scanlon, PhD, Jess DeMartino, PhD, Phyllis Torda, and Laura Long, MD, do see progress to remedy the situation and make guidelines more effective.

Payer Perspectives on the Role and Impact of QOPI Certification

January 27th 2015

Payer Perspectives on the Role and Impact of QOPI Certification

Although the healthcare industry values what it tends to measure, what is measured is not necessarily what should have the most value, according to John Fox, MD, senior medical director and associate vice president of medical affairs at Priority Health.

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

January 27th 2015

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

Education of both patients and providers will be necessary to temper expectations of cancer care treatment outcomes, according to panelists Ted Okon, BS, MBA, executive director of the Community Oncology Alliance, Debra Patt, MD, MPH, partner at Texas Oncology, and Stacie Dusetzina, PhD, assistant professor at the University of North Carolina, Chapel Hill.

Early Findings of the Oncology Patient-Centered Medical Home

January 27th 2015

Early Findings of the Oncology Patient-Centered Medical Home

One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.

January 27th 2015

CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer

The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.

January 26th 2015

Study Discovers Lack of Disease Awareness Among Women Diagnosed With Breast Cancer

The findings, published in the journal Cancer found that women diagnosed with breast cancer were not very aware of the disease characteristics such as tumor grade or stage. The researchers also found a bias based on the patient's race.

January 26th 2015

CAR T Cells and Bispecific Antibodies: A Double-Edged Sword?

Wile several big and small pharmaceutical companies have invested research efforts in developing these complex, and expensive, treatment regimens, early results from trials indicate safety issues.

January 25th 2015

ASCO Elects President for 2016-2017

Daniel F. Hayes, MD, FASCO, has been elected president of the American Society of Clinical Oncology.

...

139 140 141 142 143 144 145 146 147

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions